This trial is testing whether semaglutide can help control blood sugar and weight in people with type 2 diabetes who are also overweight, when taken with metformin. It will compare different doses of semaglutide, given by injection, to placebo (a dummy medicine). The trial will last for 52 weeks, with participants having 13 clinic visits and 4 phone calls.
Novo Nordisk Investigational Site (+54 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S